Press Release
Ivy Brain Tumor Center Announces Interim Results from a Phase 0 ‘Trigger’ Trial of Targeted Combination Therapy for Glioblastoma
The Ivy Brain Tumor Center has announced initial results from an ongoing, dual-drug Phase 0 study evaluating the tumor pharmacokinetics (PK) and tumor pharmacodynamics (PD) of abemaciclib, a selective CDK4/6-inhibitor, plus LY3214996, a selective ERK1/2 inhibitor, in recurrent glioblastoma patients.
Ivy Brain Tumor Center, SonALAsense and Insightec Announce the First Patient Dosed in First-in-Human Clinical Trial of Noninvasive Sonodynamic Therapy for the Treatment of Brain Cancer
The Ivy Center is pleased to announce the dosing of its first patient in a first-in-human Phase 0 clinical trial of sonodynamic therapy, a noninvasive drug-device combination developed by SonALAsense in collaboration with Insightec. This historic study aims to develop a nonsurgical treatment option for patients with recurrent glioblastoma and other high-grade gliomas.
First Patient Treated in Ivy Brain Tumor Center’s Phase 0 Clinical Trial of Pamiparib in Newly Diagnosed and Recurrent Glioblastoma
The Ivy Brain Tumor Center at Barrow Neurological Institute has announced the first patient has been treated in a Phase 0 clinical trial of pamiparib in newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM). This is the first Phase 0 clinical trial open to newly diagnosed glioblastoma patients.
SonALAsense Pioneers Sonodynamic Therapy, a First-in-Class Noninvasive Therapy for Lethal Brain Cancers; Enters Into a Collaboration and License Agreement With Insightec and a Collaboration Agreement with Ivy Brain Tumor Center to Conduct the First-in-Man Clinical Trial for Recurrent Glioblastoma
The Ivy Brain Tumor Center is excited to collaborate with SonALAsense to conduct this first-in-human clinical trial that will rapidly assess a noninvasive drug-device combination therapy in patients with glioblastoma.
This marks a major step forward for brain cancer patients as this novel approach has the potential to change the lives of hundreds of thousands of people impacted by this disease.
Ivy Brain Tumor Center Initiates Phase 0 Clinical Trial with BeiGene for Newly Diagnosed and Recurrent Glioblastoma
The Ivy Brain Tumor Center is conducting the first-ever Phase 0 clinical trial for newly diagnosed glioblastoma patients. This study will evaluate BeiGene’s pamiparib in combination with fractionated radiotherapy and will also be available to patients with recurrent glioblastoma.
Ivy Center Researcher Awarded Prestigious NIH Grant
Zaman Mirzadeh, MD, PhD, an assistant professor and neurosurgeon-scientist at the Ivy Brain Tumor Center and Barrow Neurological Institute, has been named a recipient of the National Institutes of Health (NIH) Director’s New Innovator Award.
Ivy Brain Tumor Center Welcomes Biostatistician to Phase 0 Clinical Trials Program
The Ivy Brain Tumor Center at Barrow Neurological Institute is pleased to announce the addition of Wonsuk Yoo, PhD, as associate professor of biostatistics. Dr. Yoo’s expertise in preclinical and clinical trial design will be critical in evaluating new treatment modalities for brain tumor patients.
Ivy Brain Tumor Center Appoints Shwetal Mehta, Ph.D., as Chief Operating Officer
The Ivy Center has appointed Shwetal Mehta, Ph.D., as its chief operating officer. Dr. Mehta is a nationally recognized molecular neuro-oncologist who has distinguished herself as a rising star in brain tumor biology.
Ivy Brain Tumor Center and Vivace Therapeutics Collaborate to Test Targeted Agent in Glioblastoma and Meningioma
Ivy Brain Tumor Center has announced a new partnership with Vivace Therapeutics. This collaboration will allow researchers at the Ivy Center to evaluate a first-in-class TEAD inhibitor in glioblastoma and meningioma.
Ivy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics announce dosing of first patient in investigator-initiated Phase 0/2 clinical trial of infigratinib in recurrent glioblastoma
The Ivy Brain Tumor Center announced that the first patient has been dosed in an investigator-initiated Phase 0/2 clinical trial of infigratinib in recurrent high-grade glioma driven by FGFR genetic alterations. Infigratinib is an investigational, orally administered, FGFR1-3 selective tyrosine kinase inhibitor being developed by BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate company QED Therapeutics, Inc.